两种吗啡依赖大鼠模型脑内单胺神经递质水平的比较

目的通过对吗啡诱导的躯体依赖与精神依赖两种大鼠模型脑内单胺类递质水平的比较,探讨其在吗啡依赖形成中的作用。方法采用剂量递增法复制吗啡依赖大鼠模型,然后用纳洛酮催促,引起躯体戒断症状。连续给予吗啡（5mg／kg,ip）6d,引起大鼠产生显著的条件性位置偏爱效应。脑组织去甲肾上腺素（NE）、5-羟色胺（5-HT）和多巴胺（DA）含量采用荧光分光光度法测定。结果吗啡依赖大鼠催促戒断后脑内NE和5-HT水平明显升高,DA水平下降。吗啡在引起大鼠明显位置偏爱的同时,使大鼠脑内DA和5-HT水平显著升高,NE无明显改变。结论吗啡依赖的形成和戒断与脑内单胺神经递质有密切关系,吗啡依赖的躯体戒断症状与NE升高有关,而吗啡诱导的精神依赖则与脑内DA水平升高有关。     

脊髓水平iNOS在吗啡依赖大鼠戒断反应中的作用

目的:探讨脊髓水平诱导型一氧化氮合酶在吗啡依赖大鼠戒断反应中的作用。方法:健康雄性SD大鼠72只,体重200~250 g,吗啡剂量每次10 mg/kg,每日2次,隔日每次增加10 mg/kg,至第6天末次注射50 mg/kg,大鼠腹腔注射纳洛酮4 mg/kg建立吗啡依赖及戒断模型,在纳洛酮激发戒断前30 min鞘内注射iNOS特异性抑制剂氨基胍(AG)150μg。分为正常对照组、吗啡依赖组、吗啡戒断组、AG组。采用行为学(n=8)、免疫组织化学(n=6)和Western blot(n=4)方法观察鞘内应用iNOS特异性抑制剂氨基胍对吗啡依赖大鼠纳洛酮催促戒断反应和脊髓神经元iNOS表达的影响。结果:AG组戒断症状评分和戒断组促诱发痛评分均低于戒断组(P<0.05)。免疫组织化学和Western blot显示戒断组大鼠脊髓iNOS阳性神经元的数目和蛋白的表达增高,而AG组大鼠脊髓iNOS阳性神经元的数目和iNOS蛋白的表达低于戒断组(P<0.05)。结论:脊髓水平iNOS表达上调可能参与介导吗啡戒断反应。     

溴隐亭和巴氯芬对吗啡诱导成瘾后戒断症状的协同抑制作用

皮下递增注射吗啡(25、50、75、100、125、150mg/kg)建立小鼠身体依赖动物模型,把6mg/kg纳络酮作用下的小鼠跳跃症状作为成瘾后戒断的行为学观测指标,检测DA受体激动剂溴隐亭和GABAB受体激动剂巴氯芬对戒断行为的影响;同时进一步研究激动二受体在戒断过程中的作用。结果表明:溴隐亭低剂量(10mg/kg)无抑制戒断症状的作用,中、高剂量(20、30mg/kg)能够明显抑制戒断症状;巴氯芬低、中剂量(0.5、1.0mg/kg)无抑制戒断症状的作用,高剂量(1.5mg/kg)则可以抑制戒断症状的作用。当无抑制作用剂量的溴隐亭(10mg/kg)和巴氯芬(1.0mg/kg)联合应用时能够明显抑制小鼠的戒断症状,说明此二受体在吗啡成瘾后戒断期间功能上具有协同作用,能够很好地抑制纳络酮诱导的成瘾小鼠跳跃症状。     

慢性吗啡依赖树鼩模型的建立

吗啡是一种有效的镇痛药,但易使动物产生耐受性和成瘾性。在该实验中,中缅树鼩(Tupai a belangeri chinensis)连续7d,每天接受三次肌肉注射递增剂量(5、10、15、20mg/kg体重)吗啡后对吗啡产生耐受和依赖;吗啡注射完成后,腹腔注射纳洛酮(1.25mg/kg体重)催瘾,可诱导其条件性位置厌恶(conditioned place aversion,CPA)及相应吗啡戒断症状的出现。该结果提示树鼩慢性吗啡依赖模型的建立可用于研究吗啡依赖和耐受的生物学机制,以及减轻戒断症状药物的筛选。     

巴氯芬对慢性吗啡依赖后条件化位置偏好和戒断症状的抑制

小鼠连续7天腹腔注射吗啡(40mg/kg)建立条件化位置偏好模型,连续皮下递增注射吗啡(25、50、75、100、125、150mg/kg),成瘾后腹腔注射纳络酮(6mg/kg)诱导戒断症状(跳跃行为)建立戒断模型。腹腔注射GABAB受体激动剂巴氯芬(2mg/kg)可以有效地抑制吗啡诱导的条件化位置偏好和减轻纳络酮诱导的戒断症状,结果表明GABA系统参与动物成瘾后渴求和戒断过程,激动GABAB受体可以在一定程度上抑制成瘾的心理和生理戒断症状。     

眼镜蛇毒细胞毒素CTXn的致死毒性及药物依赖性研究

目的研究眼镜蛇毒细胞毒素CTXn的致死毒性和药物依赖性,评价其安全性。方法检测CTXn的LD50和对肝细胞色素P450含量的影响,采用大鼠催促戒断模型、自然戒断模型及大鼠条件性位置偏爱模型检测CTXn的药物依赖性。结果 CTXn的LD50为19.61 mg/kg,长期给药对肝细胞色素P450含量无影响。在催促戒断试验中,大鼠连续腹腔注射不同剂量CTXn(0.5、1.0、2.0 mg/kg)10天后经纳洛酮催促,未出现戒断症状及体重下降现象;在大鼠自然戒断试验中,CTXn连续给药21天,停药后大鼠没有出现戒断反应及体重下降现象;在大鼠条件性位置偏爱试验中,CTXn不同剂量组分别连续用药15天后,大鼠在伴药盒的逗留时间均无明显延长,不形成条件性位置偏爱。结论 CTXn毒性较小,长期给药对肝脏药物代谢功能无影响。且不具有身体依赖性及精神依赖性,有潜在的药物开发价值。     

NO参与介导吗啡戒断大鼠脊髓神经元敏感化

运用Fos免疫组织化学、NADPH－d组织化学、F/NADPH－d双标、鞘内注射和反义寡核苷酸技术,观察吗啡戒断大鼠脊髓神经元活动变化及NO在其中的作用,结果发现：非吗啡依赖大鼠急性应用纳洛酮和吗啡依赖大鼠脊髓水平Fos-LI和NADPH－d阳性神经元表达与对照组相比无明显变化,二者也无Fos／NADPH－d双标神经元表达;吗啡依赖纳洛酮催促戒断大鼠脊髓Fos-LI、NADPH－d阳性神经元、纤维和终末表达明显增加,且出现Fos／NADPH－d双标神经元表达。Fos-LI和Fos／NADPH－d双标神经元呈现双侧脊髓全层分布,NADPH－d阳性神经元、纤维和终末主要位于双侧脊髓背角浅层。鞘内注射NOS抑制剂L－NA和nNOS反义寡核苷酸均明显降低吗啡依赖大鼠纳洛酮催促戒断症状评分,减少吗啡戒断大鼠脊髓Fos-LI表达。上述结果提示：NO参与介导吗啡戒断大鼠脊髓神经元敏感化。     

慢性吗啡处理及戒断后大鼠海马CA1区钙结合蛋白Calbindin的表达变化

目的:观察慢性吗啡处理及戒断后大鼠海马CA1区中钙结合蛋白Calbindin(CB)的表达变化,为其功能研究提供形态学依据.方法:36只雄性SD大鼠随机分为吗啡依赖组和生理盐水对照组.吗啡依赖组大鼠腹膜腔注射吗啡,2次/d,起始剂量为5mg/kg,逐日递增5mg/kg,至第10d为50mg/kg;对照组注射同体积的生理盐水.于末次注射后动物分别存活3h、3d、14d和30d.免疫组化方法和相对平均灰度值检测海马CAl区CB的表达变化.结果:在生理盐水处理组各存活时间点海马CAI区CB的表达相同.和生理盐水对照组相比,吗啡依赖组3h时海马CA1区CB的表达明显增加(P<0.05),3 d时进一步增加,至第14 d时CA1区CB的表达开始恢复.结论:慢性吗啡处理及戒断后海马CA1区CB的表达上调可能对戒断早期海马神经元有保护作用.     

鞘内注射M受体和GDNF反义寡脱氧核苷酸抑制吗啡戒断大鼠蓝斑c-Fos表达

应用免疫组化方法观察鞘内注射毒蕈碱型乙酰胆碱(muscarinic acetylcholine receptor,M) 受体和胶质细胞源性神经营养因子(glial cell derived neurotrophic factor,GDNF)反义寡脱氧核苷酸对吗啡戒断大鼠蓝斑(locus coeruleus,LC)区内Fos表达的影响。结果显示,鞘内注射M_2受体和GDNF反义寡脱氧核苷酸明显减少大鼠吗啡戒断症状评分值(n=6,P<0.05)。正常大鼠LC区神经元Fos基础表达较低,吗啡依赖大鼠LC区神经元Fos表达增加,吗啡依赖大鼠纳酪酮(4mg/Kg,ip)催促戒断后,Fos表达进一步增加;鞘内注射M_2受体和GDNF反义寡脱氧核苷酸处理后均减少吗啡戒断大鼠LC区神经元Fos表达(n=5,P<0.05)。而鞘内注射M_1受体反义寡脱氧核苷酸处理组LC 区神经元Fos表达较吗啡戒断组没有显著差异(n=5,P>O.05)。结果提示:脊髓M_2受体调节吗啡戒断时LC区的神经元激活,而这种神经上行性激活涉及神经元与胶质细胞之间的适应性调节。     

鞘内注射U0126对吗啡戒断大鼠脊髓神经元磷酸化CREB表达的影响

目的：研究鞘内注射细胞外信号调节激酶（ERK）抑制剂U0126对吗啡依赖大鼠纳洛酮催促戒断反应、脊髓磷酸化cAMP反应元件结合蛋白（p-CREB）表达的影响。方法：建立大鼠吗啡依赖和戒断模型,分为正常对照组、吗啡依赖组、吗啡戒断组、U0126组、溶媒（DMSO）组,采用行为学（n=8）、免疫组织化学（n=6）和Western blot（n=4）方法观察鞘内应用U0126对吗啡依赖大鼠纳洛酮催促戒断反应、脊髓p-CREB表达的影响。结果：①鞘内注射u0126可明显减轻吗啡依赖大鼠戒断症状,戒断组戒断症状评分为28．6±4．89,U0126组为22．5±4．09（P〈0．05）;戒断组促诱发痛评分（TEAscore）为13．5±2．55,U0126组为10．0±2．76（P〈0．05）。②鞘内注射U0126可明显减少胸腰段脊髓背角p-CREB阳性神经元的数目,U0126组为287±54,低于戒断组（380±71,P〈0．05）。 ③westem blot结果显示：鞘内注射U0126明显抑制吗啡戒断期间脊髓p-CREB表达的增加。结论：鞘内注射U0126能明显抑制吗啡戒断大鼠脊髓神经元p-CREB的表达。     

Effect of opioid agonist-antagonist interaction on morphine dependence in rats

Morphine dependence was induced by treatment with morphine-admixed food (0.25mg/g of food) for 7 days. Withdrawal was precipitated by injecting naloxone (0.5mg/kg, s.c.). Rats treated with morphine exhibited body weight loss upon the naloxone injection. When morphine-dependent rats were injected subcutaneously with morphine, codeine, meperidine and pentazocine 30 min before the naloxone injection, these drugs significantly suppressed the naloxone-precipitated loss of body weight in a dose-dependent manner. However, body weight loss induced through coadministration of naloxone and Mr-2266 BS were not suppressed by morphine pretreatment. These results suggest that opioids protect against naloxone-precipitated loss of body weight, and that mu and kappa opiate receptors play an important role in the protection against naloxone-precipitated withdrawal.     

Changes in ribonuclease in the central nervous system of mice during morphine dependence development, withdrawal and naloxone administration

Ribonuclease has been studied in the whole brain homogenate of mice after a single dose of morphine (10 mg/kg), during the development of tolerance and dependence, during the course of withdrawal and naloxone administration. The enzyme increased dose dependently following the administration of morphine. Withdrawal caused a sudden fall in the enzyme with partial recovery by the 6th day of abstinence. Naloxone injections in normal, tolerant, dependent and deprived animals caused a reduction in the enzyme level. The morphine-induced increase in enzyme activity is suggested to be in direct correlation with a reduction in protein synthesis which can be ascribed to a disturbance of the translation processes.     

Effect of withdrawal of diazepam or morphine treatment on gastric motility (charcoal meal test) in mice: possible role of different central and peripheral receptors

Increased gastrointestinal motility in mice as one of the withdrawal symptoms of commonly abused drugs like diazepam or morphine and its possible mechanism of action was studied. Male Laka mice (20-25 g) were made addict to either diazepam (20 mg/kg, ip for 7 days) or morphine (10 mg/kg, sc for 9 days). Withdrawal symptoms were noted 24 hr after the last injection of diazepam or morphine. The animals were injected with Ro 15-1788 (flumazenil) (1 mg/kg, ip) or naloxone (2 mg/kg, ip) in the respective group to precipitate the withdrawal symptoms. Gastrointestinal motility was assessed by charcoal-meal test. Animals developed tolerance to acute sedative effect of diazepam, and similarly to the acute nociceptive action of morphine. On abrupt cessation of these drugs after chronic treatment the animals showed hyperlocomotion and hyperreactivity in diazepam withdrawal group and hyperalgesia on hot plate in morphine withdrawal groups, respectively. Increase in gastrointestinal motility was observed in all the drug withdrawal groups. Treatment with respective antagonists, Ro 15-1788 (flumazenil) and naloxone precipitated the withdrawal symptoms. The results suggest the involvement of both central and peripheral receptors of benzodiazepines and opioid (mu) receptors in the withdrawal symptoms of the benzodiazepines and morphine, respectively.     

Comparison of the effects of specific and nonspecific inhibition of nitric oxide synthase on morphine analgesia,tolerance and dependence in mice

The effects of L-Canavanine, a selective inducible nitric oxide synthase (NOS) inhibitor and N(G)-nitro-L-arginine methyl ester (L-NAME), a nonselective NOS inhibitor, on pain threshold and morphine induced analgesia, tolerance and dependence in mice were investigated and compared. Morphine was administered by subcutaneous implantation of a pellet containing 40 mg free base and withdrawal was precipitated by intraperitoneal (i.p.) injection of naloxone (2 mg/kg). L-Canavanine (200 mg/kg, i.p.) did not affect the pain threshold, morphine-induced analgesia and the induction and expression phases of morphine tolerance and dependence. L-NAME (20 mg/kg, i.p.) significantly (p < 0.05) enhanced the pain threshold, potentiated morphine-induced analgesia and attenuated the expression phase of morphine dependence which has been characterized by withdrawal signs and body weight loss, but did not modify the induction phase of morphine tolerance and dependence. It is concluded that constitutive NOS isoforms which were inhibited by L-NAME may be involved specifically in the mechanisms of morphine induced analgesia, tolerance and dependence.     

Effect of methamphetamine on the development of acute morphine tolerance and dependence in mice

The effect of methamphetamine on morphine analgesia (tail-flick assay) was studied in non-tolerant mice and in mice made acutely tolerant to morphine following a single injection of 100 mg/kg morphine. The analgesic potency of morphine was increased in non-tolerant and tolerant mice to the same extent by 3.2 mg/kg methamphetamine (3.3 and 4.4 fold increases, respectively). In contrast, the ED50's for morphine analgesia and naloxone-precipitated jumping in mice pretreated with either 100 mg/kg morphine or both morphine and 3.2 mg/kg methamphetamine were not significantly different, indicating that methamphetamine had no effect on the development of acute morphine tolerance and dependence. Although methamphetamine had no effect on the development of acute tolerance to morphine, 4-day pretreatment with methamphetamine produced cross-tolerance to morphine analgesia. However, cross-tolerance to morphine was not accompanied by enchanced sensitivity to naloxone.     

脊髓蛋白激酶Cα和γ亚型在吗啡依赖和戒断反应中的不同作用

在大鼠吗啡依赖和戒断模型上,采用行为学、免疫组织化学和Western blot方法观察鞘内应用蛋白激酶C(protien kinase C,PKC)抑制剂chelerythrine chloride(CHE)对吗啡依赖大鼠纳洛酮催促成断反应、脊髓Fos蛋白表达和脊髓神经元胞膜和胞浆PKCα、γ表达的影响,以探讨不同亚型PKC在吗啡依赖和戒断反应中的作用。结果表明,鞘内注射CHE能明显减轻吗啡成断症状的评分和吗啡戒断引起的痛觉异常,抑制吗啡成断期间脊髓Fos蛋白表达的增加;吗啡依赖可引起脊髓神经元PKCα和γ表达的上调和转位：吗啡戒断期间存在明显的且可被鞘内注射CHE抑制的PKCα转位,但未观察到明显的PKCγ转位。上述结果表明,脊髓PKC表达上调和转何可能参与吗啡依赖的形成和戒断反应的表达,且PKCα和γ亚型在吗啡依赖和戒断反应中的作用存在差异。     

Evidence That Intermittent,Excessive Sugar Intake Causes Endogenous Opioid Dependence

Objective: The goal was to determine whether withdrawal from sugar can cause signs of opioid dependence. Because palatable food stimulates neural systems that are implicated in drug addiction, it was hypothesized that intermittent, excessive sugar intake might create dependency, as indicated by withdrawal signs. Research Methods and Procedures: Male rats were food‐deprived for 12 hours daily, including 4 hours in the early dark, and then offered highly palatable 25% glucose in addition to chow for the next 12 hours. Withdrawal was induced by naloxone or food deprivation. Withdrawal signs were measured by observation, ultrasonic recordings, elevated plus maze tests, and in vivo microdialysis. Results: Naloxone (20 mg/kg intraperitoneally) caused somatic signs, such as teeth chattering, forepaw tremor, and head shakes. Food deprivation for 24 hours caused spontaneous withdrawal signs, such as teeth chattering. Naloxone (3 mg/kg subcutaneously) caused reduced time on the exposed arm of an elevated plus maze, where again significant teeth chattering was recorded. The plus maze anxiety effect was replicated with four control groups for comparison. Accumbens microdialysis revealed that naloxone (10 and 20 mg/kg intraperitoneally) decreased extracellular dopamine (DA), while dose‐dependently increasing acetylcholine (ACh). The naloxone‐induced DA/ACh imbalance was replicated with 10% sucrose and 3 mg/kg naloxone subcutaneously. Discussion: Repeated, excessive intake of sugar created a state in which an opioid antagonist caused behavioral and neurochemical signs of opioid withdrawal. The indices of anxiety and DA/ACh imbalance were qualitatively similar to withdrawal from morphine or nicotine, suggesting that the rats had become sugar‐dependent.     

Enhanced prolactin inhibition following chronic treatment with haloperidol and morphine

Withdrawal from chronic haloperidol or morphine treatment resulted in lower circulating levels of serum prolactin in male rats. A low dose of apomorphine (0.32 mg/kg), which had no effect on serum prolactin in untreated rats, diminished serum prolactin in the treated rats. A lower dose of apomorphine (0.08 mg/kg) also ineffective in control rats, elevated serum prolactin in the treated rats.     

Different Effects of Opiate Withdrawal on Dopamine Turnover,Uptake, and Release in the Striatum and Nucleus Accumbens

The purpose of these experiments was to further characterize changes in dopaminergic function that follow withdrawal from chronic opiate treatment. Withdrawal after treatment to a maximum dose of 120 mg/kg of morphine did not alter dopamine concentrations in the substantia nigra, ventral tegmental area, striatum, or nucleus accumbens; but did decrease concentrations of DOPAC and the ratio of DOPAC to dopamine in the lateral striatum and nucleus accumbens. Uptake of tritiated dopamine was diminished for withdrawn slices obtained from the striatum with no effect observed for tissue from the nucleus accumbens. Deficits of in vitro release of tritiated dopamine also occurred following withdrawal, with the nucleus accumbens being sensitive to dependence produced by a lower dose of morphine. In conclusion, opiate withdrawal produces a complex pattern of effects on dopaminergic function that is specific for the striatum and nucleus accumbens.